Management of post-transplant diabetes

Current Diabetes Reports

Volumn 13, Issue 1, 2013, Pages 121-129

  Therasse, Ashley ^a   Wallia, Amisha ^a   Molitch, Mark E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Calcineurin; Corticosteroids; Cyclosporine; Diabetes; Exenatide; Glipizide; Glucose; Heart; Hyperglycemia; Immunosuppression; Insulin; Kidney; Linagliptin; Liraglutide; Liver; Lung; Metformin; NODAT; Saxagliptin; Sirolimus; Sitagliptin; Tacrolimus; Transplantation

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIPROLIFERATIVE AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INSULIN; INSULIN ASPART; INSULIN GLARGINE; LINAGLIPTIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEGLITINIDE; METFORMIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PREDNISONE; RAPAMYCIN; REPAGLINIDE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRAFT REJECTION; AGE DISTRIBUTION; ANTIDIABETIC ACTIVITY; ARTICLE; BLOOD GLUCOSE MONITORING; BOLUS INJECTION; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG PULSE THERAPY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLUID RETENTION; FRACTURE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLYCEMIC CONTROL; HEPATITIS C; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY DYSFUNCTION; LIFESTYLE MODIFICATION; LIPODYSTROPHY; LIVER DYSFUNCTION; LOW DRUG DOSE; NEW ONSET DIABETES MELLITUS AFTER TRANSPLANT; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; OSTEOLYSIS; PANCREATITIS; PATIENT EDUCATION; POSTOPERATIVE INFECTION; RHINOPHARYNGITIS; RISK FACTOR; SIDE EFFECT; STEROID INDUCED HYPERGLYCEMIA; SURVIVAL; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

DIABETES MELLITUS; HUMANS; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE AGENTS; INPATIENTS; RISK FACTORS; TRANSPLANTATION;

EID: 84872611399     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-012-0346-8     Document Type: Article

References (77)

1. Montori VM, Basu A, Erwin PJ, et al. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care. 2002;25:583-92.
2. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation. 2003;75(10 Suppl):SS3-24. This article presents the most recent guidlines regarding the diagnosis and treatment of new onset diabetes after solid organ transplant.
3. Collins AJ, Foley RN, Chavers B, et al. United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis. 2012;59(1 Suppl 1):A7, e1-420.
4. Ganji MR, Charkhchian M, Hakemi M, et al. Association of hyperglycemia on allograft function in the early period after renal transplantation. Transplant Proc. 2007;39:852-4. (Pubitemid 46764872)
5. Hosseini MS, Nemati E, Pourfarziani V, et al. Early hyperglycemia after allogenic kidney transplantation: does it induce infections. Ann Transplant. 2007;12:23-6.
6. Cosio FG, Pesavento TE, Kim S, et al. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int. 2002;62:1440-6.
7. Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant. 2003;3:590-8. (Pubitemid 36612842)
8. American Diabetes A. Standards of Medical Care in Diabetes-2012. Diabetes Care. 2012;35 Suppl 1:S11-63. This article covers the most recent guidelines for the diagnosis and management of type 2 diabetes.
9. van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest. 2009;39:81-93.
10. Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association Consensus statement on inpatient glycemic control. Diabetes Care. 2009;32:1119-31.
11. Umpierrez GE, Hellman R, Korytkowski MT, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2012;97:16-38. This article provides recommendations for the inpatient management of hyperglycemia in non-ICU patients.
12. Cosio FG, Kudva Y, van der Velde M, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int. 2005;67:2415-21. (Pubitemid 41623405)
13. Cosio FG, Pesavento TE, Osei K, et al. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int. 2001;59:732-7. (Pubitemid 32157939)
14. Salvadori M, Bertoni E, Rosati A, Zanazzi M. Post-transplant diabetes mellitus. J Nephrol. 2003;16:626-34. (Pubitemid 38714245)
15. Sumrani NB, Delaney V, Ding ZK, et al. Diabetes mellitus after renal transplantation in the cyclosporine era-an analysis of risk factors. Transplantation. 1991;51:343-7.
16. Depczynski B, Daly B, Campbell LV, et al. Predicting the occurrence of diabetes mellitus in recipients of heart transplants. Diabet Med. 2000;17:15-9. (Pubitemid 30094175)
17. Baid S, Cosimi AB, Farrell ML, et al. Post-transplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation. 2001;72:1066-72. (Pubitemid 32924079)
18. Bloom RD, Rao V, Weng F, et al. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol. 2002;13:1374-80. (Pubitemid 34441419)
19. Markell M. New-onset diabetes mellitus in transplant patients: pathogenesis, complications, and management. Am J Kidney Dis. 2004;43:953-65. (Pubitemid 38691490)
20. Luan FL, Steffick DE, Ojo AO. New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. Transplantation. 2011;91:334-41.
21. Hjelmesaeth J, Hartmann A, Kofstad J, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation. 1997;64:979-83. (Pubitemid 27446762)
22. Hollander AA, Hene RJ, Hermans J, et al. Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study. J Am Soc Nephrol. 1997;8:294-301. (Pubitemid 127455885)
23. Vincenti F, Jensik SC, Filo RS, et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation. 2002;73:775-82. (Pubitemid 34260577)
24. Rostambeigi N, Lanza IR, Dzeja PP, et al. Unique cellular and mitochondrial defects mediate FK506-induced islet beta-cell dysfunction. Transplantation. 2011;91:615-23.
25. Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant. 2004;4:583-95. (Pubitemid 38523581)
26. Xu X, Ling Q, He ZL, et al. Post-transplant diabetes mellitus in liver transplantation: Hangzhou experience. Hepatobiliary Pancreat Dis Int. 2008;7:465-70.
27. Drachenberg CB, Klassen DK, Weir MR, et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation. 1999;68:396-402. (Pubitemid 29384108)
28. Penninga L, Møller CH, Gustafsson F, et al. Tacrolimus vs cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials. Eur J Clin Pharmacol. 2010;66:1177-87.
29. Ghisdal L, Bouchta NB, Broeders N, et al. Conversion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature. Transpl Int. 2008;21:146-51.
30. Gyurus E, Kaposztas Z, Kahan BD. Sirolimus therapy predisposes to new-onset diabetes mellitus after renal transplantation: a long-term analysis of various treatment regimens. Transplant Proc. 2011;43:1583-92.
31. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 2003;35(3 Suppl):7S-14. (Pubitemid 36547910)
32. Araki M, Flechner SM, Ismail HR, et al. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. Transplantation. 2006;81:335-41. This trial demonstrated that older age, obesity, steroid pulse therapy, and tacrolimus use all increased the risk of developing NODAT. (Pubitemid 43255716)
33. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-79.
34. Rassias AJ, Marrin CA, Arruda J, et al. Insulin infusion improves neutrophil function in diabetic cardiac surgery patients. Anesth Analg. 1999;88:1011-6. (Pubitemid 29211530)
35. Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol. 1999;26(3-4):259-65.
36. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345:1359-67.
37. Finfer S, Chittock DR, Su SY, et al. Intensive vs conventional glucose control in critically ill patients. N Engl J Med. 2009;360:1283-97.
38. Ammori JB, Sigakis M, Englesbe MJ, et al. Effect of intraoperative hyperglycemia during liver transplantation. J Surg Res. 2007;140:227-33. (Pubitemid 46726378)
39. Thomas MC, Mathew TH, Russ GR, et al. Early peri-operative glycaemic control and allograft rejection in patients with diabetes mellitus: a pilot study. Transplantation. 2001;72:1321-4. (Pubitemid 33026616)
40. Thomas MC, Moran J, Mathew TH, et al. Early peri-operative hyperglycaemia and renal allograft rejection in patients without diabetes. BMC Nephrol. 2000;1:1. (Pubitemid 38892502)
41. Wallia A, Parikh ND, Molitch ME, et al. Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection. Transplantation. 2010;89:222-6.
42. Wallia A, Parikh ND, O'Shea-Mahler E, et al. Glycemic control by a Glucose Management Service and infection rates following liver transplantation. Endocr Pract. 2011;17:546-51.
43. Finfer S, Liu B, Chittock DR, et al. Hypoglycemia and risk of death in critically ill patients. N Engl J Med. 2012;367:1108-18.
44. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011;34:1431-7.
45. Sambol NC, Chiang J, Lin ET, et al. Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol. 1995;35:1094-102.
46. Frid A, Sterner GN, Londahl M, et al. Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations. Diabetes Care. 2010;33:1291-3.
47. Rachmani R, Slavachevski I, Levi Z, et al. Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. Eur J Intern Med. 2002;13:428-33.
48. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;4:CD002967.
49. Nye HJ, Herrington WG. Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract. 2011;118:c380-3.
50. Pilmore HL. Review: metformin: potential benefits and use in chronic kidney disease. Nephrology. 2010;15:412-8.
51. Jonsson A, Rydberg T, Sterner G, Melander A. Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. Eur J Clin Pharmacol. 1998;53:429-35. (Pubitemid 28154743)
52. Rosenkranz B, Profozic V, Metelko Z, et al. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia. 1996;39:1617-24. (Pubitemid 26397377)
53. Asplund K, Wiholm BE, Lundman B. Severe hypoglycaemia during treatment with glipizide. Diabet Med. 1991;8:726-31.
54. Nagai T, Imamura M, Iizuka K, Mori M. Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure. Diabetes Res Clin Pract. 2003;59:191-4. (Pubitemid 36183302)
55. Inoue T, Shibahara N, Miyagawa K, et al. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol. 2003;60:90-5. (Pubitemid 36975183)
56. Schumacher S, Abbasi I, Weise D, et al. Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol. 2001;57:147-52. (Pubitemid 32449136)
57. Hasslacher C. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care. 2003;26:886-91. (Pubitemid 36929360)
58. Zhu Z, Shen Z, Lu Y, et al. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: A meta-analysis. Diabetes Res Clin Pract. 2012;98:408-14.
59. Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int. 2008;19:129-37.
60. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol. 2009;5:26298:408-14.9.
61. Glorie LL, Verhulst A, Matheeussen V, et al. DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury. Am J Physiol. 2012;303:F681-8.
62. Zhai W, Cardell M, De Meester I, et al. Intragraft DPP IV inhibition attenuates post-transplant pulmonary ischemia/reperfusion injury after extended ischemia. J Heart Lung Transplant. 2007;26:174-80. (Pubitemid 46136044)
63. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care. 2010;33:2349-54.
64. Graefe-Mody U, Retlich S, Friedrich C. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clin Pharmacokinet. 2012;51:411-27.
65. Linnebjerg H, Kothare PA, Park S, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol. 2007;64:317-27. (Pubitemid 47283860)
66. Johansen OE, Whitfield R. Exenatide may aggravate moderate diabetic renal impairment: a case report. Br J Clin Pharmacol. 2008;66:568-9.
67. Weise WJ, Sivanandy MS, Block CA, Comi RJ. Exenatide-associated ischemic renal failure. Diabetes Care. 2009;32:e22-3.
68. Pendergrass M, Fenton C, Haffner SM, Chen W. Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis. Diabetes Obes Metabol. 2012;14:596-600.
69. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol. 2009;68:898-905.
70. Ghofaili KA, Fung M, Ao Z, et al. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation. 2007;83:24-8. (Pubitemid 46104966)
71. Froud T, Faradji RN, Pileggi A, et al. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. Transplantation. 2008;86:36-45.
72. Rickels MR, Mueller R, Markmann JF, Naji A. Effect of glucagon-like peptide-1 on beta- and alpha-cell function in isolated islet and whole pancreas transplant recipients. J Clin Endocrinol Metab. 2009;94:181-9.
73. Wilkinson A, Davidson J, Dotta F, et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant. 2005;19:291-8. (Pubitemid 40711959)
74. Muhlhauser I, Toth G, Sawicki PT, Berger M. Severe hypoglycemia in type I diabetic patients with impaired kidney function. Diabetes Care. 1991;14:344-6.
75. Hasslacher C, Wittmann W. Severe hypoglycemia in diabetics with impaired renal function. Dtsch Med Wochenschr. 2003;128:253-6. (Pubitemid 36207870)
76. Baldwin D, Zander J, Munoz C, et al. A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency. Diabetes Care. 2012;35:1970-4.
77. Watt KD, Charlton MR. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol. 2010;53:199-206.